Skip to content

Author

Yangbo Feng

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.

Though 100 kinase inhibitors are approved for clinical use, most kinases in the genome remain poorly characterized. Moreover, though kinase inhibitors have revolutionized the care of selected cancers, most others respond transiently or not at all to these drugs, typically directed against signal-transduction pathways....

Olivia B. Farag, Bassel Awada, A. Youssfi et al. · 0 citations
Jul 2026

Abstract B085: Selective oral STK17A inhibitor UMF814A targets a previously unrecognized dark kinase vulnerability in spliceosome-mutant MDS and AML

Myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) remain therapeutically challenging, particularly in patients with spliceosome-mutant disease, where effective targeted options are lacking. Mutations in SF3B1, SRSF2, and U2AF1 define a biologically distinct subset associated with aberrant RNA splic...

E. Spinetti, C. C. Pastrana, E. Bravo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.